Pfizer, Incorporated v. Lott, Ricky ( 2005 )


Menu:
  •                             In the
    United States Court of Appeals
    For the Seventh Circuit
    ____________
    No. 05-8013
    PFIZER, INC.,
    Petitioner,
    v.
    RICKY LOTT, et al., individually and
    on behalf of all others similarly situated,
    Respondents.
    ____________
    Petition for Leave to Appeal from the
    United States District Court for
    the Southern District of Illinois.
    No. 05-cv-230-MJR—Michael J. Reagan, Judge.
    ____________
    SUBMITTED JULY 14, 2005—DECIDED AUGUST 4, 2005
    ____________
    Before BAUER, POSNER, and WOOD, Circuit Judges.
    POSNER, Circuit Judge. Pfizer, sued in a class action in an
    Illinois state court, removed the suit to federal district court,
    which remanded it to the state court on the ground that
    there was no federal jurisdiction. The suit charged Pfizer
    with having overcharged for two drugs in violation of state
    consumer-protection law. There was no federal claim, and
    so the only possible basis of federal jurisdiction was diver-
    2                                                  No. 05-8013
    sity of citizenship. The named plaintiffs stipulated that they
    would not seek or even accept damages in excess of $75,000,
    and while the stipulation would not bind the other members
    of the class, Manguno v. Prudential Property & Casualty Ins.
    Co., 
    276 F.3d 720
    , 724 (5th Cir. 2002), the likelihood that any
    purchaser of either drug had damages in excess of $75,000
    was sufficiently remote (In re Brand Name Prescription Drugs
    Antitrust Litigation, 
    123 F.3d 599
    , 607 (7th Cir. 1997); see also
    Garbie v. DaimlerChrysler Corp., 
    211 F.3d 407
    , 410 (7th Cir.
    2000)) to cast on Pfizer the burden of presenting some
    evidence or argument to establish the plausibility of an
    inference that at least one member of the class could cross
    the $75,000 threshold, American Bankers Life Assurance Co. v.
    Evans, 
    319 F.3d 907
    , 909 (7th Cir. 2003), which would
    establish jurisdiction over the entire class. Exxon Mobil Corp.
    v. Allapattah Service, Inc., 
    125 S. Ct. 2611
     (2005).
    But Pfizer had another string to its bow. The Class Action
    Fairness Act of 2005, Pub. L. 109-2, 
    119 Stat. 4
    , provides that
    the minimum amount in controversy is satisfied if the
    aggregate stakes in a class action exceed $5 million, as it
    plainly does in this case. The rub is that the suit was filed in
    the state court the day before the Act was enacted, although
    the complaint was served afterwards and the suit was
    removed to the federal district court within the 30 days that
    are permitted for removing from state court a suit that is
    within the jurisdiction of the federal courts. 
    28 U.S.C. § 1446
    (b). The Class Action Fairness Act is applicable only
    to suits “commenced on or after” the date of enactment, and
    the district judge ruled that this meant the date on which
    the suit was filed in the state court, not the date of removal.
    Pfizer asks us to permit it to appeal from this determination.
    Fed. R. App. P. 5, 27. Although remands to state court are
    ordinarily nonappealable, the new Act makes an exception
    for remands of suits removed under it. 
    28 U.S.C. § 1453
    (c).
    No. 05-8013                                                  3
    We are tempted to deny the petition with just a citation to
    Knudsen v. Liberty Mutual Ins. Co., 
    411 F.3d 805
     (7th Cir.
    2005), which holds (following Pritchett v. Office Depot, Inc.,
    
    404 F.3d 1232
     (10th Cir. 2005), the only other appellate case
    to address the issue), that “commenced” indeed means
    “filed” rather than “removed.” But as Pfizer points out,
    there is a difference between the present case on the one
    hand and Knudsen and Pritchett on the other. In Knudsen the
    suit had been filed five years, and in Pritchett two years,
    before removal. The ordinary deadline for removal is
    30 days, as we said, though there is an exception for cases in
    which removal doesn’t become possible until later, 
    28 U.S.C. § 1446
    (b); Benson v. SI Handling Systems, Inc., 
    188 F.3d 780
    ,
    782 (7th Cir. 1999), and the defendants pointed out that
    removal first became possible when the Class Action
    Fairness Act was passed. If that argument for removal
    prevailed, then as we noted in Knudsen the Act would have
    a dramatic retroactive effect. In contrast, removal here
    occurred within the 30-day deadline.
    Nevertheless we think Knudsen and Pritchett should gov-
    ern this case as well. While it is true that the proceeding in
    federal court was “commenced” by the filing of the removal
    petition, that filing was not the beginning of the suit. For
    what was removed was the suit that had been brought in
    the Illinois state court, and under Illinois law the filing of
    the complaint had “commenced” the suit. 735 ILCS 5/2-201;
    Kohlhaas v. Morse, 
    183 N.E.2d 16
    , 19 (Ill. App. 1962). Nothing
    changed except the forum. The principle is recognized in
    decisions involving the transfer of cases that were filed in
    the wrong forum initially; the transfer does not commence
    a new suit for purposes of deciding whether the suit is
    timely. E.g., Phillips v. Seiter, 
    173 F.3d 609
    , 610 (7th Cir.
    1999). Moreover, were Pfizer’s reading adopted, we would
    have to rewrite the statute in order to create an exception for
    4                                                   No. 05-8013
    cases such as Knudsen and Pritchett in which the removed
    suit had been filed more than 30 days before removal. That
    necessity suggests that Pfizer’s reading is incorrect. The
    injustice of which it complains is not so great as to justify
    radical judicial surgery on the statute.
    This is not to belittle Pfizer’s indignation at the plaintiffs’
    having beat the statute by one day, but their gamesmanship
    actually hurts its argument. Pharmaceutical and other
    companies that pressed for the enactment of the Class
    Action Fairness Act were doubtless acutely aware, as the bill
    that became the statute was wending its way through
    Congress en route to enactment, that the prospect of its
    enactment would spur the class action bar to accelerate the
    filing of state-law class actions in state courts. Doubtless the
    companies made their concerns known to Congress. The fact
    that Congress did not respond by writing “removed” (or
    “removed after the date of enactment but within 30 days of
    the original filing”) instead of “commenced” is telling.
    The petition to appeal is
    DENIED.
    No. 05-8013                                             5
    A true Copy:
    Teste:
    _____________________________
    Clerk of the United States Court of
    Appeals for the Seventh Circuit
    USCA-02-C-0072—8-4-05
    6   No. 05-8013